Inari Medical (NASDAQ:NARI) Given New $67.00 Price Target at Robert W. Baird

Inari Medical (NASDAQ:NARI) had its price target hoisted by Robert W. Baird from $66.00 to $67.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other brokerages have also weighed in on NARI. Wells Fargo & Company reduced their price objective on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a report on Wednesday, October 9th. Truist Financial reduced their price objective on shares of Inari Medical from $55.00 to $46.00 and set a “hold” rating on the stock in a report on Monday, October 14th. William Blair assumed coverage on shares of Inari Medical in a report on Thursday, July 25th. They issued an “outperform” rating on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $58.89.

Inari Medical Stock Up 0.7 %

Inari Medical stock opened at $48.74 on Tuesday. The firm has a market cap of $2.85 billion, a PE ratio of -35.90 and a beta of 1.00. Inari Medical has a 52-week low of $36.73 and a 52-week high of $67.13. The company’s 50 day moving average is $43.56 and its two-hundred day moving average is $45.99.

Inari Medical (NASDAQ:NARI) last released its earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). The business had revenue of $145.82 million for the quarter, compared to analyst estimates of $143.96 million. Inari Medical had a negative return on equity of 10.09% and a negative net margin of 13.68%. On average, equities research analysts anticipate that Inari Medical will post -0.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Inari Medical news, CFO Mitch C. Hill sold 5,000 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $47.99, for a total transaction of $239,950.00. Following the transaction, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at approximately $8,619,004. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at $22,265,500. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 131,000 shares of company stock valued at $6,161,340. Insiders own 10.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Inari Medical in the first quarter valued at about $30,000. GAMMA Investing LLC boosted its holdings in shares of Inari Medical by 164.7% in the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after acquiring an additional 438 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after acquiring an additional 435 shares in the last quarter. Covestor Ltd boosted its holdings in shares of Inari Medical by 30.2% in the first quarter. Covestor Ltd now owns 1,619 shares of the company’s stock valued at $78,000 after acquiring an additional 376 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after acquiring an additional 522 shares in the last quarter. 90.98% of the stock is owned by hedge funds and other institutional investors.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.